Structural basis for the inhibition of Trypanosoma brucei enolase by a camelid single-domain antibody
Li, Z.; Smiejkowska, N.; Vansevenant, J.; Mertens, J.; Van Wielendaele, P.; Pinto Torres, J. E.; Magez, S.; Sterckx, Y. G.
Show abstract
Trypanosoma brucei is an extracellular protozoan that causes neglected tropical diseases in both humans and livestock. The parasite has a bipartite life cycle involving an insect vector and a mammalian host. Within the latter, it mainly thrives as a blood-borne parasite that relies on glycolysis to support its energy metabolism. It is for this reason that trypanosomal glycolytic enzymes have been investigated as potential targets for the development of trypanosome-killing drugs. Recent work from our lab has shown that they are also interesting biomarkers for the detection of active trypanosome infections. T. brucei enolase (TbrENO) is a trypanosomal glycolytic enzyme that has gathered interest in both drug and diagnostics development. In this paper, we report the discovery of a camelid single domain antibody (sdAb aka nanobody) that specifically recognises and inhibits TbrENO. The sdAbs inhibitory mechanism is unraveled through a combination of protein biochemistry, biophysics, and structural biology. Author summaryTrypanosoma brucei is a unicellular parasite that lives in the bloodstream of humans and animals, where it causes serious but often overlooked diseases. Because it depends heavily on breaking down glucose to produce energy, the parasites glucose-processing proteins (called glycolytic enzymes) have become important targets for both new treatments and improved diagnostic tools. One of these proteins, called T. brucei enolase (TbrENO), has recently drawn attention for its potential in drug development and disease detection. In this study, we discovered a special type of antibody, known as a camelid single-domain antibody (sdAb aka nanobody), that can specifically recognize and block the activity of TbrENO. We employed a combination of various laboratory techniques to understand exactly how the sdAb binds to and inhibits the enzyme. Our findings provide new insight into how TbrENO can be inhibited in a way that does not require active site binding and highlight the value of sdAbs as precise tools for targeting key parasite proteins.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Structural insights into acetylated histone ligand recognition by the BDP1 bromodomain of Plasmodium falciparum 94%
- Optimized pipeline for generating highly potent neutralizing Affitins: application to SARS-CoV-2 spike protein 93%
- Vibrio campbellii chitoporin: thermostability study and implications for the development of therapeutic agents against Vibrio infections 93%
Similar papers in this journal
- Itaconate utilisation by the human pathogen Pseudomonas aeruginosa requires uptake via the IctPQM TRAP transporter 94%
- A viral SAVED protein with ring nuclease activity degrades the CRISPR second messenger cA4 94%
- Characterisation of RNA guanine-7 methyltransferase (RNMT) using a small molecule approach 93%
Similar papers in this journal
- Hydroxylation of antitubercular drug candidate, SQ109, by mycobacterial cytochrome P450 95%
- The Solvation of the E. coli CheY Phosphorylation SiteMapped by XFMS 93%
- How do gepotidacin and zoliflodacin stabilize DNA-cleavage complexes with bacterial type IIA topoisomerases? 1. Experimental definition of metal binding sites 93%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.